Curis

Curis

MA - Lexington
Biotechnology
WebsiteLinkedInCareers Page

Focus: Small Molecules

Curis is a life sciences company focused on Small Molecules.

Oncology
Open Jobs
0

Pipeline & Clinical Trials

Phase 1
Clinical Trials (1)
NCT02812875A Study of CA-170 (Oral PD-L1, PD-L2 and VISTA Checkpoint Antagonist) in Patients With Advanced Tumors and Lymphomas
Phase 1
fimepinostat
Lymphoma
Phase 1
Clinical Trials (1)
NCT01742988Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymphoma
Phase 1
CUDC-101
Tumors
Phase 1
Clinical Trials (1)
NCT00728793A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of CUDC-101 in Patients With Advanced Solid Tumors
Phase 1
Phase 1
Clinical Trials (1)
NCT07107750Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer
Phase 1
CUDC-907
Lymphoma
Phase 1
Clinical Trials (1)
NCT02909777Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma
Phase 1
Phase 1
Clinical Trials (1)
NCT02307240Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced/Relapsed Solid Tumors
Phase 1
CUDC-427
Lymphoma
Phase 1
Clinical Trials (1)
NCT01908413Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-427 When Given to Patients With Advanced and Refractory Solid Tumors or Lymphoma
Phase 1
Phase 1
Clinical Trials (1)
NCT01171924A Phase Ib Expansion Study Investigating the Safety, Efficacy, and Pharmacokinetics of Intravenous CUDC-101 in Subjects With Advanced Head and Neck, Gastric, Breast, Liver and Non-small Cell Lung Cancer Tumors
Phase 1
CUDC-101
Cancer
Phase 1
Clinical Trials (1)
NCT01702285Phase I Study to Assess the Safety, Tolerability, and Pharmacokinetics of Orally Administered CUDC-101 in Cancer Patients
Phase 1
Phase 1
Clinical Trials (1)
NCT03893487Fimepinostat in Treating Brain Tumors in Children and Young Adults
Phase 1
Phase 1
Clinical Trials (1)
NCT05187182CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer
Phase 1
Phase 1
Clinical Trials (1)
NCT01384799Phase I Study of CUDC-101 With Cisplatin and Radiation in Subjects With Head & Neck Cancer
Phase 1
Phase 1
Clinical Trials (1)
NCT04475523Phase 1 Study of CI-8993 Anti-VISTA Antibody in Patients With Advanced Solid Tumor Malignancies
Phase 1
Phase 1/2
Clinical Trials (1)
NCT04278768Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Phase 1/2
Phase 1/2
Clinical Trials (1)
NCT03328078CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Phase 1/2
Phase 2
Clinical Trials (1)
NCT07271667A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies
Phase 2
Phase 2
Clinical Trials (1)
NCT05178342Treatment of Anemia in Patients With Very Low, Low or Intermediate Risk Myelodysplastic Syndromes With CA-4948
Phase 2
Phase 2
Clinical Trials (1)
NCT02674750Study to Evaluate the Efficacy and Safety of CUDC-907 in Patients With RR DLBCL, Including Patients With MYC Alterations
Phase 2
chondrocyte-alginate gel suspension
Vesicoureteral Reflux
Phase 3
Clinical Trials (1)
NCT00004487Phase III Study of Chondrocyte Alginate Gel Suspension in Pediatric Patients With Vesicoureteral Reflux
Phase 3

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts
Portfolio: 19 clinical trials

Hiring Trend

Stable
0
Open Roles
+0
Added
-0
Filled/Removed

Based on last 4 crawl cycles